• Raised $125.9M in capital in 2024, including IPO
• R&D costs increased 66.6% to $51.5M in 2024
• Received Q4 2025 regulatory approvals to start PARADIGM pivotal study

Anteris Technologies, a global structural heart company, presented its Annual Meeting CEO Presentation, providing an update on the company's progress. In 2024, Anteris raised $125.9M in capital, including through an IPO, and ended the year with $70.5M in cash, compared to $21.1M at the end of 2023. R&D costs increased 66.6% to $51.5M in 2024, as the company focused on key initiatives such as the PARADIGM trial preparatory costs, expansion of the clinical field team, upscaling manufacturing capabilities, and the DurAVR valve development program. In Q4 2025, Anteris received regulatory approvals to start the PARADIGM pivotal study in Denmark and the U.S. The company also completed a $25.2M private placement in Q4 2025. Anteris has built a strong, global workforce of 159.9 FTEs as of September 2025, with a focus on diversity and inclusion. The company's re-domiciliation to the U.S. and Nasdaq listing in 2024 have significantly increased its liquidity and access to capital. Anteris is well-positioned to advance its DurAVR Transcatheter Heart Valve technology, which is designed to restore healthy heart function, through the PARADIGM trial and regulatory approvals.